1. 2022
  2. Immunodeficiency, autoimmunity, and increased risk of B cell malignancy in humans with TRAF3 mutations

    Rae, W., Sowerby, J. M., Verhoeven, D., Youssef, M., Kotagiri, P., Savinykh, N., Coomber, E. L., Boneparth, A., Chan, A., Gong, C., Jansen, M. H., du Long, R., Santilli, G., Simeoni, I., Stephens, J., Wu, K., Zinicola, M., Allen, H. L., Baxendale, H., Kumararatne, D. & 17 others, Gkrania-Klotsas, E., Scheffler Mendoza, S. C., Yamazaki-Nakashimada, M. A., Ruiz, L. B., Rojas-Maruri, C. M., Lugo Reyes, S. O., Lyons, P. A., Williams, A. P., Hodson, D. J., Bishop, G. A., Thrasher, A. J., Thomas, D. C., Murphy, M. P., Vyse, T. J., Milner, J. D., Kuijpers, T. W. & Smith, K. G. C., 12 Aug 2022, In: Science immunology. 7, 74, p. eabn3800

    Research output: Contribution to journalArticleAcademicpeer-review

  3. Treatment of an HLH-mimic disease based on HAVCR2 variants with absent TIM-3 expression

    Tromp, S. A. M., Gillissen, M. A., Bernelot Moens, S. J., van Leeuwen, E. M. M., Jansen, M. H., Koens, L., Rutten, C. E. & Kuijpers, T. W., 9 Aug 2022, In: Blood advances. 6, 15, p. 4501-4505 5 p.

    Research output: Contribution to journalComment/Letter to the editorAcademic

  4. Partial RAG deficiency in humans induces dysregulated peripheral lymphocyte development and humoral tolerance defect with accumulation of T-bet+ B cells

    Csomos, K., Ujhazi, B., Blazso, P., Herrera, J. L., Tipton, C. M., Kawai, T., Gordon, S., Ellison, M., Wu, K., Stowell, M., Haynes, L., Cruz, R., Zakota, B., Nguyen, J., Altrich, M., Geier, C. B., Sharapova, S., Dasso, J. F., Leiding, J. W., Smith, G. & 30 others, Al-Herz, W., de Barros Dorna, M., Fadugba, O., Fronkova, E., Kanderova, V., Svaton, M., Henrickson, S. E., Hernandez, J. D., Kuijpers, T., Kandilarova, S. M., Naumova, E., Milota, T., Sediva, A., Moshous, D., Neven, B., Saco, T., Sargur, R., Savic, S., Sleasman, J., Sunkersett, G., Ward, B. R., Komatsu, M., Pittaluga, S., Kumanovics, A., Butte, M. J., Cancro, M. P., Pillai, S., Meffre, E., Notarangelo, L. D. & Walter, J. E., 1 Aug 2022, In: Nature immunology. 23, 8, p. 1256-1272 17 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  5. Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report

    van der Veer, M. A. A., Jacobs, T. G., Bukkems, L. H., Colbers, A. P. H., Burger, D. M., Scherpbier, H. J. & Bijleveld, Y. A., 1 Aug 2022, In: Antiviral therapy. 27, 4

    Research output: Contribution to journalArticleAcademicpeer-review

  6. Comorbidities, clinical characteristics and outcomes of COVID-19 in pediatric patients in a tertiary medical center in the Netherlands

    Biharie, A., Keuning, M. W., Wolthers, K. C. & Pajkrt, D., Aug 2022, In: World Journal of Pediatrics. 18, 8, p. 558-563 6 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  7. Including the voice of paediatric patients: Cocreation of an engagement game

    Teela, L., Verhagen, L. E., Gruppen, M. P., Santana, M. J., Grootenhuis, M. A. & Haverman, L., Aug 2022, In: Health expectations. 25, 4, p. 1861-1871 11 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  8. Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod

    Target-to-B! (T2B!) SARS-CoV-2 study group, 1 Jul 2022, In: Neurology® neuroimmunology & neuroinflammation. 9, 4

    Research output: Contribution to journalArticleAcademicpeer-review

  9. Optimized Protocols for In-Vitro T-Cell-Dependent and T-Cell-Independent Activation for B-Cell Differentiation Studies Using Limited Cells

    the T2B Consortium, 29 Jun 2022, In: Frontiers in immunology. 13, 815449.

    Research output: Contribution to journalArticleAcademicpeer-review

  10. Practical Workflow for Cardiovascular Assessment and Follow-Up in Kawasaki Disease Based on Expert Opinion

    van Stijn, D., Planken, R. N., Groenink, M., Blom, N., de Winter, R. J., Kuijpers, T. & Kuipers, I., 9 Jun 2022, In: Frontiers in pediatrics. 10, 873421.

    Research output: Contribution to journalArticleAcademicpeer-review

  11. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies

    T2B! immunity against SARS-CoV-2 study group, 1 Jun 2022, In: The Lancet Rheumatology. 4, 6, p. e417-e429

    Research output: Contribution to journalArticleAcademicpeer-review

Previous 1 2 3 4 5 6 7 8 ...126 Next

ID: 19980